CAMPBELL, Calif.--(BUSINESS WIRE)--Imperative Care, Inc., a company singularly dedicated to finding answers to unsolved problems in stroke, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its first family of access catheters, designed to deliver interventional treatments during minimally invasive neurovascular procedures for aneurysms, stroke and other brain blood vessel conditions.
“Recognizing the significant need to elevate the standard of patient therapeutics in stroke, Imperative Care was founded to become the comprehensive stroke company innovating across the entire continuum of care,” said Fred Khosravi, Imperative Care’s founding chairman and CEO, and the co-founder and co-managing director of Incept LLC. “Our approach is informed by a unique clinical perspective, along with a keen appreciation that this underserved medical category requires a holistic commitment and focus to make better stroke treatment modalities available to more patients around the world.”
Imperative Care is the twenty-first company co-founded by Incept LLC, a medical technology accelerator and development company that has successfully innovated various medical technologies that treat more than a million patients a year globally.
“We are now in a brand new era in stroke treatment. The field has been revolutionized in recent years with more modern imaging modalities, therapeutic technologies, and clinical rigor identifying the importance of the timing of intervention. All of these important advancements have underscored that, as in the treatment of acute myocardial infarctions, improved mechanical solutions to physically open the blocked brain artery will continue to offer clear advantages for improved patient outcomes,” said Imperative Care co-founder L. Nelson “Nick” Hopkins, M.D., who is also founder and chief scientific officer of the Jacobs Institute in Buffalo, New York. “Stroke no longer has to be a death or disability sentence. With new technologies, more patients will be able to return to normal lives following a stroke.”
Imperative Care’s first products are neurovascular access catheters designed to enable smooth, consistent navigation deep into blood vessels of the brain, which can be challenging because of the brain’s highly complex and twisted vascular structure. The catheters are designed to enable physicians to navigate to the treatment site with greater control and flexibility – critical to successful neurovascular procedures, where every minute counts – without sacrificing support or stability. These catheters will be launched at select centers in the United States in the coming months.
“Getting to the brain is the necessary and first step in any procedure. Imperative Care’s new access catheters are designed to provide a platform that facilitates easier navigation through complex vasculature. This should help physicians treat patients more quickly, giving them the best chance at an optimal recovery,” said Reade De Leacy, M.D., assistant professor of Neurosurgery and Radiology, and site director of Cerebrovascular Services at Mount Sinai Queens, who performed the first clinical case.
Imperative Care is also developing a pipeline of technologies designed to help clinicians improve the effectiveness and speed of acute stroke treatment, with the goal of enabling better patient outcomes. The company’s near-term pipeline includes an aspiration treatment catheter designed to facilitate rapid clot removal.
About Imperative Care, Inc.
Based in Campbell, Calif., Imperative Care is speeding new answers to stroke by developing a portfolio of innovative solutions to address the vast and urgent unmet needs in stroke care. The company is singularly dedicated to improving the way stroke is treated by advancing medical technology, equipping healthcare providers to evolve best practices and elevate the standard of care for stroke patients. For more information, visit http://www.imperativecare.com/.
Dr. De Leacy is a paid consultant for Imperative Care, Inc.